ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
F-star Therapeutics Announces First Patient Dosed in FS120 Trial americanpharmaceuticalreview
December 24, 2020F-star Therapeutics has announced the first patient has been dosed in its Phase 1 trial evaluating FS120, a first-in-class dual-agonist tetravalent bispecific antibody targeting CD137 (4-1BB, TNFRSF9) and OX40 (CD134, TNFRSF4).
Pharma Sources Insight January 2025
